Does the expert panel at the St Gallen meeting provide an unbiased opinion about the management of women with early breast cancer?

Annals of Oncology

Volumn 20, Issue 10, 2009, Pages 1749-1751

  Hietanen, Paivi ^a  

^a Suomen Laakariliitto   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; TAMOXIFEN;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CANCER THERAPY; CONFLICT OF INTEREST; DISEASE FREE SURVIVAL; DRUG COST; DRUG INDUSTRY; EARLY CANCER; FEMALE; HUMAN; LETTER; MEDICAL EXPERT; OVERALL SURVIVAL; POSTMENOPAUSE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; CONFLICT OF INTEREST; CONGRESSES AS TOPIC; CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; FEMALE; HUMANS; INTERNATIONAL COOPERATION; MEDICAL ONCOLOGY; PRACTICE GUIDELINES AS TOPIC; SWITZERLAND; TIME FACTORS;

EID: 70349642286     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp399     Document Type: Letter

References (19)

1. Goldhirsch A, Glick JH, Gelber RD et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005; 16: 1569-1583.
2. Goldhirsch A, Wood WC, Gelber RD et al. Progress and promise: Highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007; 18: 1133-1144.
3. Coates AS, Keshaviah A, Thurlimann B et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98. J Clin Oncol 2007; 25: 486-492.
4. Coombes RC, Kilburn LS, Snowdon CF et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): A randomised controlled trial. Lancet 2007; 369: 559-570.
5. Forbes JF, Cuzick J, Buzdar A et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008; 9: 45-53.
6. Seruga B, Tannock IF. Up-front use of aromatase inhibitors as adjuvant therapy for breast cancer: The emperor has no clothes. J Clin Oncol 2009; 27: 840-842.
7. Blumenthal D. Doctors and drug companies. N Engl J Med 2004; 351: 1885-1890.
8. Cain DM, Detsky AS. Everyone's a little bit biased (even physicians). JAMA 2008; 299: 2893-2895.
9. Dana J, Loewenstein G. A social science perspective on gifts to physicians from industry. JAMA 2003; 290: 252-255.
10. Wazana A. Physicians and the pharmaceutical industry: Is a gift ever just a gift? JAMA 2000; 283: 373-380.
11. Kassirer JP. On the Take: How Medicine's Complicity with Big Business Can Endanger Your Health. New York: Oxford University Press 2004; 97-99.
12. Sniderman AD, Furberg CD. Why guideline-making requires reform. JAMA 2009; 301: 429-431.
13. Somerfield MR, Einhaus K, Hagerty KL et al. American Society of Clinical Oncology clinical practice guidelines: Opportunities and challenges. J Clin Oncol 2008; 26: 4022-4026.
14. Campbell EG, Gruen RL, Mountford J et al. A national survey of physician-industry relationships. N Engl J Med 2007; 356: 1742-1750.
15. DeAngelis CD, Fontanarosa PB. Impugning the integrity of medical science: The adverse effects of industry influence. JAMA 2008; 299: 1833-1835.
16. Rothman DJ. Academic medical centers and financial conflicts of interest. JAMA 2008; 299: 695-697.
17. Rothman DJ, Chimonas S. New developments in managing physician-industry relationships. JAMA 2008; 300: 1067-1069.
18. Ehringhaus SH, Weissman JS, Sears JL et al. Responses of medical schools to institutional conflicts of interest. JAMA 2008; 299: 665-671.
19. Rothman DJ, McDonald WJ, Berkowitz CD et al. Professional medical associations and their relationships with industry. A proposal for controlling conflict of interest. JAMA 2009; 301: 1367-1372.